Related Experiment Video
Updated: Jul 8, 2026
09:14
The Rabbit Model of Accelerated Atherosclerosis: A Methodological Perspective of the Iliac Artery Balloon Injury
Published on: October 3, 2017
12.1K
Angiographic Safety and Efficacy of the ReSolv Flow-Diverting Stent in a Rabbit Model
Rosalie Ea Morrish1, Alec T Chunta1, Brooke L Belanger1,2
1Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Summary
The novel ReSolv bioresorbable stent demonstrated promising safety and efficacy in a rabbit aneurysm model, with high occlusion rates and no significant stenosis. Further long-term studies are underway to assess the stent
Area of Science:
- Biomaterials Science
- Medical Devices
- Vascular Surgery
Background:
- Bioresorbable polymer stents offer potential advantages over traditional metal stents.
- The ReSolv device is a novel, primarily polymer-based flow-diverting stent.
- Evaluating new devices in animal models is crucial for clinical translation.
Purpose of the Study:
- To assess the safety and efficacy of the ReSolv flow-diverting stent.
- To utilize the in vivo rabbit sidewall saccular aneurysm model for evaluation.
- To determine the stent's performance in terms of patency, stenosis, apposition, and occlusion.
Main Methods:
- ReSolv stents were implanted in 14 rabbits with induced aneurysms.
- Animals were followed for up to 18 months, with angiographic evaluation at various time points.
- Key outcomes included in-stent stenosis, vessel patency, wall apposition, and aneurysm occlusion (RROC, O'Kelly Marotta, 4F scores).
Main Results:
- All parent vessels (14/14) and jailed side branches (33/33) remained patent.
- No thrombus formation or significant in-stent stenosis was observed; good wall apposition was achieved.
- Adequate aneurysm occlusion (RROC Class I or II) was achieved in 85.7% of cases.
Conclusions:
- The ReSolv stent shows encouraging angiographic safety and efficacy in a rabbit aneurysm model.
- Longer-term studies are needed to evaluate the stent's fate after polymer absorption.
- These findings support the potential of bioresorbable stents for aneurysm treatment.
Related Concept Videos
01:29Blood Flow
Blood is pumped by the heart into the aorta, the largest artery in the body, and then into increasingly smaller arteries, arterioles, and capillaries. The velocity of blood flow decreases with increased cross-sectional blood vessel area. As blood returns to the heart through venules and veins, its velocity increases. The movement of blood is encouraged by smooth muscle in the vessel walls, the movement of skeletal muscle surrounding the vessels, and one-way valves that prevent backflow.
00:57Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
01:30Typical Model Studies
Fluid mechanics model studies often utilize scaled-down systems to predict fluid behavior in full-scale environments, such as river flows, dam spillways, and structures interacting with open surfaces. Maintaining Froude number similarity in river models is crucial, as it replicates surface flow features like wave patterns and velocities.